Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model: Geneva, Switzerland Wednesday, April 22, 2026, 18:00 Hrs [IS ...

Initial clinical focus for TNV108 is on peripheral neuropathies Tenvie Therapeutics has dosed the first participant in its ...

Second candidate from Tenvie’s product engine to enter clinical developmentPhase 1 first-in-human study to evaluate single and multiple ascending ...

RNA transcripts containing the hammerhead ribozyme have been engineered to self-destruct in the presence of specific nucleoside 3′,5′-cyclic monophosphate compounds. These RNA molecular switches were ...

G protein-coupled receptors (GPCRs) are intrinsically allosteric proteins. Through spatially distinct, but conformationally linked, binding sites they have evolved to transduce signals from one part ...

HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...

HotSpot Therapeutics, a new drug discovery venture exploring protein regulation, has kicked off with $45 million in series A financing. Co-founded by Nimbus veterans Geraldine Harriman and Jonathan ...

The study also clarifies the functional role of the receptor's conserved sodium-binding pocket, showing that sodium egress strongly promotes activation-related conformational states, including a ...

A publication from Acta Pharmaceutica Sinica B discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a debilitating ...

BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. Background: ...

Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...